Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib

Mennitto, Alessia; Verzoni, Elena; Peverelli, Giorgia; Alessi, Alessandra; Procopio, Giuseppe

doi:10.1016/j.clgc.2018.03.010

Cited by 18 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case report revealed a partial metabolic response by PET after 3 months of first-line therapy with cabozantinib in a patient with multiple bone metastases. 27 In our cohort of four patients with collecting duct tumours, we observed encouraging disease control (50% objective response, 100% clinical benefit); however, this finding is caveated by the small sample size. BONSAI (), a single-arm phase 2 trial evaluating cabozantinib in untreated collecting duct renal cell carcinoma, will provide more definitive data.…”

Section: Discussionmentioning

confidence: 61%

“…When stratified by line of systemic therapy, treatment naive versus previously treated, the proportion of patients who achieved an objective response was 23% (95% CI 8-45) versus 28% (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38), and 12-month overall survival was 60% (95% CI 29-81) versus 49% (36-61), respectively. When analysed according to type of previous therapies, the proportion of patients who achieved an objective response was 28% (95% CI 15-45) in those who had tyrosine kinase inhibitor therapy only, 33% (10-65) in those who had immunotherapy only, and 28% (14-45) in those who had both therapies; and 12-month overall survival was 54% (95% CI 36-70) versus 27% (1-66) versus 48% (28-66), respectively.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Chanzá

Xie

Bilen

et al. 2019

The Lancet Oncology

138

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Resultsmentioning

confidence: 99%

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Chanzá

Xie

Bilen

et al. 2019

The Lancet Oncology

138

View full text Add to dashboard Cite

show abstract

“…Therefore, even though the most common approach for systemic therapy is platinum-based chemotherapy, there may also be a role for targeted therapies in this setting. Nevertheless, even though there are some other case reports that could suggest some activity with targeted therapies (21)(22)(23)(24)(25), there are also other studies with no response to these agents (26)(27)(28).…”

Section: Discussionmentioning

confidence: 99%

Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors

Pinto¹,

Garrido

Aguado

et al. 2019

KCA

View full text Add to dashboard Cite

Introduction: Collecting duct carcinomas (CDC), also known as Bellini's tumors, are a rare and aggressive subtype of renal cell carcinoma. Therefore, there are very few data about their management, and there is no standard therapy for this malignancy. We report the outcome of CDC patients treated on institutions belonging to the 'Grupo Centro' of Genitourinary Tumors, a novel networking cooperative group in Spain. Material and Methods: Patients with CDC diagnosed between 1995 and 2015 were included. They had to have an appropriate follow-up, as well as available tissue for further correlative studies. Demographic baseline features and therapy outcomes were collected in a retrospective fashion. Approval for this data collection was obtained from a central ethical committee. Results: A total of 43 patients were analysed, with a median overall survival (OS) of 14 months (95% CI: 9.2-18.8 months). 29 of them (67.4%) were diagnosed as localized disease, and 14 (32.6%) as metastatic disease. For the subgroup of patients diagnosed without metastases, median relapse-free survival (RFS) is 22 months (95% CI: 12.4-35.6 months), and median OS, 53 months (95% CI: 35.5-84.3 months). For the subgroup of patients with metastatic disease, median OS is 6 months (95% CI: 4.1-7.8 months). 16 patients (55.2%) with stage IV disease received systemic therapy, mainly platinum-based chemotherapy, with a response rate of 12.5% and a median progression-free survival (PFS) of 2 months. Conclusions: CDC of the kidney is a malignancy with poor prognosis and few responses to therapy. Median OS of our group in the metastatic setting is similar to what has been observed in previous series. There is a clear need to improve the armamentarium we have for the systemic approach of patients with advanced CDC.

show abstract

“…Microscopically, it has a tubular or tubulopapillary architecture[ 1 , 4 , 10 ]. The World Health Organization established major criteria for diagnosing CDC, which is a diagnosis of exclusion.…”

Section: Introductionmentioning

confidence: 99%

Cystic low-grade collecting duct renal carcinoma with liver compression — A challenging diagnosis and therapy: A case report

Fülöp

Gurzu

Jung

et al. 2020

WJGS

View full text Add to dashboard Cite

BACKGROUND A collecting duct carcinoma is a very rare, malignant renal epithelial tumor. Distant metastases are present in one third of cases at the time of diagnosis. It is known to have a poor prognosis. CASE SUMMARY A 42-year-old male was sent to our surgery clinic for removal of a 119.2 mm × 108.3 mm encapsulated cystic mass, which was localized in the 8 th segment of the right liver lobe. The lesion was first identified on ultrasonography. A computed tomography scan confirmed the presence of a Bosniak type III cystic lesion, which affected the liver and convexity of the right kidney. Surgical intervention involved a right nephrectomy, with removal of the cystic mass. The patient was mobilized on the first postoperative day and was discharged after 7 d. The histological and immunohistochemical examination revealed a low-grade collecting duct renal carcinoma, which is a rare variant of papillary carcinoma, with low malignant potential. The patient did not receive chemotherapy and after 21 mo of follow-up, a radiological examination and laboratory analyses showed normal aspects. No relapse or other complications were reported. CONCLUSION To manage renal tumors properly, a correct histopathological diagnosis is crucial, as is early diagnosis and correct surgical treatment.

show abstract

Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib

Cited by 18 publications

References 8 publications

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors

Cystic low-grade collecting duct renal carcinoma with liver compression — A challenging diagnosis and therapy: A case report

Contact Info

Product

Resources

About